TransCon® PTH (Palopegteriparatide) Demonstrates Sustained, Clinically Meaningful Improvements in Kidney Function in Adults with Hypoparathyroidism Treated Up to 5 Years
At final trial visits, most patients were independent of active vitamin D and therapeutic calcium doses.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Ascendis Pharma (ASND) reported sustained kidney-function improvements in adults with hypoparathyroidism treated with TransCon PTH for up to five years. The post-hoc pooled analysis included 139 treated patients from Phase 2 PaTH Forward and Phase 3 PaTHway. Mean estimated glomerular filtration rate (eGFR), a kidney-function measure, rose 7.2 mL/min/1.73 m2 at Week 26 and 9.6 at Week 52 from baseline. At Week 52, 68.9% achieved increases of at least 5 mL/min/1.73 m2; improvements persisted through trial completion.
Mean urine calcium fell from 396 mg/day at baseline to 170 mg/day at Week 52. At final visits, 98% were independent of active vitamin D and 95% of therapeutic calcium doses; 88% had normal albumin-adjusted serum calcium. No new safety signals emerged. Long-term follow-up was open-label, and 129 patients completed the final visit.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Positive
- Moderate pointMean eGFR increased 7.2 mL/min/1.73 m2 at Week 26 and 9.6 at Week 52 versus baseline.
- Minor pointeGFR increases were statistically significant from Week 26 through trial completion (p<0.0001).
- Minor pointWeek 52 eGFR gains reached ≥5 mL/min/1.73 m2 in 68.9% and >10 in 49.6% of patients.
- Minor pointMean eGFR slope was 0.28 mL/min/1.73 m2/year from Weeks 52–266, supporting sustained early improvements.
- Minor pointPatients with baseline eGFR <60 mL/min/1.73 m2 had numerically greater mean increases than those at ≥60.
6 minor points
- Minor pointMean urine calcium normalized to 206 mg/day at Week 26, from 396 at baseline; reached 170 at Week 52.
- Minor pointUrine calcium improvements were sustained through the end of the trials.
- Minor pointActive vitamin D independence reached 98% at final visits, defined as no calcitriol or alfacalcidol.
- Minor pointTherapeutic calcium independence reached 95% at final visits, defined as taking <600 mg/day.
- Minor pointMean serum calcium increased within the normal range to 8.9 mg/dL; 88% had normal albumin-adjusted levels at final visits.
- Minor pointSafety findings showed no new signals; most treatment-emergent adverse events were mild to moderate.
Negative
- Minor pointKidney findings came from a post-hoc pooled analysis, rather than a prospectively specified pooled assessment.
- Minor pointPlacebo-controlled periods ended at Weeks 4 and 26; subsequent extensions were open-label.
- Minor pointFinal trial visits were completed by 129 of 139 treated patients in the pooled analysis.
- Minor pointTrial eligibility required eGFR ≥30 mL/min/1.73 m2, limiting the population studied.
Key Figures
- Mean eGFR improvement
- 7.2 mL/min/1.73 m2
- From baseline to Week 26
- Mean eGFR improvement
- 9.6 mL/min/1.73 m2
- From baseline to Week 52
- Patients with eGFR improvement ≥5
- 68.9%
- By Week 52
- Patients with eGFR increase >10
- 49.6%
- By Week 52
- eGFR statistical significance
- p<0.0001
- Increases from Week 26 through trial completion
- 24-hour urine calcium
- 396 mg/day at baseline; 206 mg/day at Week 26; 170 mg/day at Week 52
- Mean excretion
- Independence from active vitamin D
- 98%
- At final trial visit
- Independence from therapeutic calcium
- 95%
- At final trial visit
Historical Context
-
Five-year bone mass and microarchitecture normalization in the same PaTH Forward and PaTHway trials.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
pth medical
post-hoc technical
teaes medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
COPENHAGEN, Denmark, Oct. 26, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced new data demonstrating early, sustained, and clinically meaningful improvements in kidney function in adults with hypoparathyroidism treated with TransCon® PTH (palopegteriparatide) for up to 5 years in the Company’s Phase 2 PaTH Forward and Phase 3 PaTHway trials. Results from the pooled analysis were shared in a poster presented by nephrologist Elvira Gosmanova, M.D., Professor of Medicine at Albany Medical College, during Kidney Week 2026, the annual meeting of the American Society of Nephrology.
“These groundbreaking improvements in renal function underscore the unique ability of TransCon PTH to replicate the systemic and balanced actions of endogenous PTH across multiple target organ systems,” said Aimee Shu, Executive Vice President and Chief Medical Officer at Ascendis Pharma. “We are pleased to showcase these benefits of TransCon PTH showing simultaneous improvements across key measures that include maintained normal serum calcium, decreased urine calcium, and sustained increases in eGFR, while enabling independence from conventional therapy.”
Historically, management of hypoparathyroidism with conventional therapy consisting of active vitamin D and calcium with the aim of raising serum calcium to the lower half or just below the reference range to alleviate symptoms of hypocalcemia and avoid hypercalciuria, but did not address the missing parathyroid hormone (PTH).i Today, in contrast, it is possible to provide or restore the full range of effects of PTH that are missing in hypoparathyroidism with TransCon PTH, which provides active PTH within the physiological range for 24 hours/day. The active PTH released from TransCon PTH includes the amino acid sequence identical to the region of endogenous PTH required for receptor activation and enables simultaneous improvements across multiple key clinical and quality-of-life measures.ii,iii
Data Highlights
- Increases in mean estimated glomerular filtration rate (eGFR) from baseline were statistically significant across patients from Week 26 of treatment through trial completion (p< 0.0001).
- Mean improvement in eGFR for all patients from baseline to Week 26 was 7.2 mL/min/1.73 m2 and to Week 52 was 9.6 mL/min/1.73 m2.
- By Week 52, clinically meaningful improvements in eGFR (≥ 5 mL/min/1.73 m2) iv,v were observed in
68.9% of patients, and49.6% of patients achieved an increase in eGFR of >10 mL/min /1.73 m2; eGFR remained stable through the end of the trials. - From Week 52 to Week 266, the mean eGFR slope was 0.28 mL/min/1.73 m2/year, indicating clinically meaningful early improvements in eGFR sustained through up to 5 years, in contrast to the expected typical age-related decline in eGFR in adults.vi
- Patients with baseline eGFR values < 60 mL/min/1.73 m2 had a numerically greater increase in mean eGFR than those with a baseline eGFR ≥ 60 mL/min/1.73 m2.
- 24-hour urine calcium excretion normalized by Week 26 from mean 396 mg/day at baseline to mean 206 mg/day at Week 26 and further decreased from Week 26 to mean 170 mg/day at Week 52, with improvements sustained through the end of the trials.
98% of patients achieved independence from active vitamin D, defined as taking no calcitriol or alfacalcidol, at final trial visit.95% of patients achieved independence from therapeutic doses of calcium, defined as taking <600 mg/day of calcium, at final trial visit.- Mean serum calcium increased within the normal range to 8.9 mg/dL, with
88% of patients having normal albumin-adjusted serum calcium levels at final trial visit. - In both trials, TransCon PTH was generally well tolerated, with no new safety signals identified. Most treatment-emergent adverse events (TEAEs) were mild to moderate (Grade 1 or 2).
The PaTH Forward and PaTHway trials included a combined total of 141 adults with hypoparathyroidism. The pooled kidney data analysis covers the 139 patients who received at least one dose of TransCon PTH. Of these, 129 completed the final trial visit. The PaTH Forward and PaTHway trials comprised randomized, double-blind, placebo-controlled periods through Weeks 4 and 26 and open-label extension periods through Weeks 266 and 182, respectively. An eGFR ≥30 mL/min/1.73 m2 was required for trial eligibility. Mean (SD) baseline eGFR for the pooled analysis was 69 (17) mL/min/1.73 m2. The pooled data were analyzed post-hoc and included evaluation of the impact of TransCon PTH on renal function, as assessed by, change from baseline in eGFR and proportion of patients with an increase in eGFR ≥5 mL/min/1.73 m2, as well as 24-hour urinary calcium.
About TransCon PTH
TransCon PTH is a prodrug of PTH (1-34), administered once daily, designed to provide active PTH within the physiological range for 24 hours/day, approved as YORVIPATH® in the United States, European Union, European Economic Area, and other jurisdictions as a treatment for adults with hypoparathyroidism.
About Hypoparathyroidism
Hypoparathyroidism is an endocrine disease caused by insufficient levels of parathyroid hormone (PTH), the primary regulator of calcium and phosphate balance in the body, acting directly on bone and kidney and indirectly on the intestine. Individuals with hypoparathyroidism may experience a range of severe and potentially life-threatening short-term and long-term complications, including neuromuscular irritability, renal complications, extra-skeletal calcifications, and cognitive impairment. Post-surgical hypoparathyroidism accounts for the majority of cases (70
About Ascendis Pharma A/S
Ascendis Pharma is a global biopharmaceutical company focused on applying our innovative TransCon technology platform to make a meaningful difference for patients. Guided by our core values of Patients, Science, and Passion, and following our algorithm for product innovation, we apply TransCon to develop new therapies that demonstrate best-in-class potential to address unmet medical needs. Ascendis is headquartered in Copenhagen, Denmark, and has additional facilities in Europe and the United States. Please visit ascendispharma.com to learn more.
Forward-Looking Statements
This press release contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this press release regarding Ascendis’ future operations, plans and objectives of management are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Examples of such statements include, but are not limited to, statements relating to (i) TransCon PTH (palopegteriparatide) data from the Phase 2 PaTH Forward and Phase 3 PaTHway trials, (ii) TransCon PTH’s ability to replicate the systemic and balanced actions of endogenous PTH across multiple target organ systems and to provide or restore the full range of effects of PTH that are missing in hypoparathyroidism, (iii) TransCon PTH’s differentiated profile, including its potential to show simultaneous improvements across key measures while enabling independence from conventional therapy, (iv) Ascendis’ ability to apply its TransCon technology platform to make a meaningful difference for patients, and (v) Ascendis’ use of TransCon to develop new and potentially best-in-class therapies to address unmet medical needs. Ascendis may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in the forward-looking statements and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions, expectations and projections disclosed in the forward-looking statements. Various important factors could cause actual results or events to differ materially from the forward-looking statements that Ascendis makes, including, without limitation: dependence on third-party manufacturers, distributors, and service providers for Ascendis’ products and product candidates; risks related to regulatory review and approval, including the possibility of delays, requests for additional data or analyses, restrictions or limitations on use, approval with labeling that is more limited than expected, or failure to obtain approval in the United States, European Union, or other jurisdictions; clinical development risks, including that results from ongoing or future trials may not confirm earlier data; unforeseen safety or efficacy findings in development programs or on-market products; manufacturing, supply chain, quality, or logistics issues that could delay development or commercialization; unforeseen expenses related to commercialization of any approved Ascendis products; unforeseen research and development or selling, general and administrative expenses and other costs impacting Ascendis’ business generally; market acceptance, pricing, and reimbursement challenges, including payer coverage decisions and health technology assessments; competitive developments, including new or improved therapies; intellectual property protection, freedom-to-operate, and litigation risks; Ascendis’ ability to obtain additional funding, if needed, to support its business activities; cybersecurity, data privacy, and information technology disruptions; and the impact of international economic, political, legal, compliance, public health, and business factors, including tariffs, trade policies, currency fluctuations, and geopolitical events. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Ascendis’ business in general, see Ascendis’ Annual Report on Form 20-F filed with the U.S. Securities and Exchange Commission (SEC) on February 11, 2026, and Ascendis’ other future reports filed with, or submitted to, the SEC. Forward-looking statements do not reflect the potential impact of any future licensing, collaborations, acquisitions, mergers, dispositions, joint ventures, or investments that Ascendis may enter into or make. Ascendis does not assume any obligation to update any forward-looking statements, except as required by law.
Ascendis, Ascendis Pharma, the Ascendis Pharma logo, the company logo, TransCon, and YORVIPATH® are trademarks owned by the Ascendis Pharma group. © October 2026 Ascendis Pharma A/S.
| Investor Contact: | Media Contact: |
| Chad Fugere | Melinda Baker |
| Ascendis Pharma | Ascendis Pharma |
| +1 (650) 519-7494 | +1 (650) 709-8875 |
__________________________________
i Khan AA, Bilezikian JP, Brandi ML, et al. J Bone Miner Res. 2022; 37(12):2568-2585.
ii Holten-Andersen L, Pihl S, Rasmussen CE, et al. J Bone Miner Res. Nov 2019;34(11):2075-2086. doi:10.1002/jbmr.3824.
iii Karpf DB, Pihl S, Mourya S, et al. J Bone Miner Res. Aug 2020;35(8):1430-1440. doi:10.1002/jbmr.4016.
iv Mayne TJ, et al. Clin Transplant. 2021;35(7):e14326.
v Ku E, et al. J Am Soc Nephrol. 2016;27(7):2196-204.
vi Guppy M et al. BMJ Open. 2024;14(11):e089783. doi:10.1136/bmjopen-2024-089783.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What kidney-function improvements did Ascendis Pharma report for TransCon PTH?
Mean eGFR increased from baseline by 7.2 mL/min/1.73 m2 at Week 26 and 9.6 mL/min/1.73 m2 at Week 52. At Week 52, 68.9% of patients achieved increases of ≥5 mL/min/1.73 m2, and 49.6% achieved increases of >10 mL/min/1.73 m2.
How many TransCon PTH patients stopped needing active vitamin D and therapeutic calcium doses?
At final trial visits, 98% achieved independence from active vitamin D and 95% from therapeutic calcium doses. Active vitamin D independence meant taking no calcitriol or alfacalcidol. Therapeutic calcium independence meant taking <600 mg/day of calcium.
How long were the placebo-controlled and extension periods in Ascendis Pharma's TransCon PTH trials?
PaTH Forward and PaTHway had randomized, double-blind, placebo-controlled periods through Weeks 4 and 26, respectively. Their open-label extensions continued through Weeks 266 and 182, respectively. Eligibility required eGFR ≥30 mL/min/1.73 m2; mean baseline eGFR in the pooled analysis was 69 mL/min/1.73 m2.